AstraZeneca PLC ADR (AZN) is a leading drug manufacturers - general business based in the US. It opened the day at $63.89 after a previous close of $63.80. During the day the price has varied from a low of $62.88 to a high of $63.93. The latest price was $63.20 (25 minute delay). AstraZeneca PLC ADR is listed on the NASDAQ and employs 89,900 staff. All prices are listed in US Dollars.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Open | $0.00 |
|---|---|
| High | $0.00 |
| Low | $0.00 |
| Close | $0.00 |
| Previous close | $0.00 |
| Change | $0.00 |
| Change % | N/A% |
| Volume | 0 |
| 52-week range | $59.19 - $87.68 |
|---|---|
| 50-day moving average | $75.43 |
| 200-day moving average | $74.76 |
| Wall St. target price | $90.37 |
| PE ratio | 31.4203 |
| Dividend yield | $2.97 (2.28%) |
| Earnings per share (TTM) | $2.07 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $63.2 from 2024-11-19
| 1 week (2024-11-13) | -3.20% |
|---|---|
| 1 month (2024-10-18) | -19.24% |
| 3 months (2024-08-20) | -25.76% |
| 6 months (2024-05-20) | -18.04% |
| 1 year (2023-11-20) | -0.92% |
|---|---|
| 2 years (2022-11-18) | 1.33% |
| 3 years (2021-11-19) | 19.13% |
| 5 years (2019-11-20) | 51.74% |
Valuing AstraZeneca PLC ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AstraZeneca PLC ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AstraZeneca PLC ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, AstraZeneca PLC ADR shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
AstraZeneca PLC ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7268. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca PLC ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AstraZeneca PLC ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $18.4 billion.
The EBITDA is a measure of a AstraZeneca PLC ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $51.2 billion |
|---|---|
| Operating margin TTM | 20.4% |
| Gross profit TTM | $35.7 billion |
| Return on assets TTM | 8.5% |
| Return on equity TTM | 16.66% |
| Profit margin | 12.68% |
| Book value | $26.27 |
| Market Capitalization | $201.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 46.3% of net profits
Recently AstraZeneca PLC ADR has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AstraZeneca PLC ADR shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In AstraZeneca PLC ADR's case, that would currently equate to about $2.97 per share.
While AstraZeneca PLC ADR's payout ratio might seem fairly standard, it's worth remembering that AstraZeneca PLC ADR may be investing much of the rest of its net profits in future growth.
AstraZeneca PLC ADR's most recent dividend payout was on 8 September 2024. The latest dividend was paid out to all shareholders who bought their shares by 8 August 2024 (the "ex-dividend date").
AstraZeneca PLC ADR's shares were split on a 2:1 basis on 26 July 2015 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your AstraZeneca PLC ADR shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for AstraZeneca PLC ADR shares which in turn could have impacted AstraZeneca PLC ADR's share price.
Over the last 12 months, AstraZeneca PLC ADR's shares have ranged in value from as little as $59.1911 up to $87.675. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AstraZeneca PLC ADR's is 0.18. This would suggest that AstraZeneca PLC ADR's shares are less volatile than average (for this exchange).
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.